This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jones, R. N.
Right arrow Articles by Morrissey, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, R. N.
Right arrow Articles by Morrissey, I.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2003, p. 2696-2698, Vol. 47, No. 8
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.8.2696-2698.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Quinupristin-Dalfopristin Resistance in Streptococcus pneumoniae: Novel L22 Ribosomal Protein Mutation in Two Clinical Isolates from the SENTRY Antimicrobial Surveillance Program

Ronald N. Jones,1* David J. Farrell,2 and Ian Morrissey2

The JONES Group/JMI Laboratories, North Liberty, Iowa,1 GR Micro, Ltd., London, United Kingdom2

Received 17 January 2003/ Returned for modification 27 March 2003/ Accepted 24 May 2003

Resistance to quinupristin-dalfopristin (Q/D) among gram-positive cocci has been very uncommon. Two clinical isolates among 8,837 (0.02%) Streptococcus pneumoniae isolates were discovered in 2001 to 2002 with Q/D MICs of 4 µg/ml. Each had a 5-amino-acid tandem duplication (RTAHI) in the L22 ribosomal protein gene (rplV) preventing synergistic ribosomal binding of the streptogramin combination. Similar gene duplication has been reported in Q/D-resistant Staphylococcus aureus.

* Corresponding author. Mailing address: The JONES Group/JMI Laboratories, Inc., 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317. Phone: (319) 665-3370. Fax: (319) 665-3371. E-mail: ronald-jones{at}jmilabs.com.

Antimicrobial Agents and Chemotherapy, August 2003, p. 2696-2698, Vol. 47, No. 8
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.8.2696-2698.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Obert, C. A., Miller, M. L., Montgomery, J., Adamkiewicz, T., Tuomanen, E. I. (2007). Quinupristin-Dalfopristin Nonsusceptibility in Pneumococci from Sickle Cell Disease Patients. Antimicrob. Agents Chemother. 51: 386-389 [Abstract] [Full Text]  
  • Farrell, D. J., Morrissey, I., Bakker, S., Buckridge, S., Felmingham, D. (2004). In Vitro Activities of Telithromycin, Linezolid, and Quinupristin-Dalfopristin against Streptococcus pneumoniae with Macrolide Resistance Due to Ribosomal Mutations. Antimicrob. Agents Chemother. 48: 3169-3171 [Abstract] [Full Text]  
  • Achour, W., Guenni, O., Malbruny, B., Canu, A., Leclercq, R., Ben Hassen, A. (2004). Phenotypic and molecular characterization of macrolide and streptogramin resistance in Streptococcus mitis from neutropenic patients. J Antimicrob Chemother 54: 117-121 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»